Trial Profile

A phase III study of GSK916 + Standard of Care (SOC) vs. SOC in first line transplant ineligible multiple myeloma patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab mafodotin (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms DREAMM-9
Sponsors GlaxoSmithKline; GSK

Most Recent Events

14 Nov 2024 According to an GSK media release, this study is expected to be initiated by the end of 2024 as part of the DREAMM programme.
04 Jun 2020 According to an GlaxoSmithKline media release, data from this study will be presented at the 25th European Hematology Association (EHA) Annual Congress from 11-21 June 2020.
28 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com